4726 Share Price Performance
Recent 4726 News & Updates
No updates
Mycenax Biotech Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.22
- Gross Margin
- -32.14%
- Net Profit Margin
- -63.50%
- Debt/Equity Ratio
- 46.3%
Mycenax Biotech Inc. Competitors
About 4726
- Founded
- 2001
- Employees
- n/a
- CEO
- WebsiteView website
Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company’s services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers plasmid DNA, antibody-drug conjugates, cell and gene therapy, and exosomes products and services. The company was founded in 2001 and is headquartered in Zhubei, Taiwan.
Taiwanese Market Performance
- 7 Days: 0.6%
- 3 Months: 12.7%
- 1 Year: 2.4%
- Year to Date: 2.3%
In the last week, the market has stayed flat, however the Energy sector stood out, gaining 9.2%. In line with that, the market has also been flat over the past year. Earnings are forecast to grow by 13% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading